Alnylam’s HELIOS-B Review: Conflicting Insights Analyzed by Lilu Anderson 25.06.2024 Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
European GRANOLAS: 30% Discount InvestmentleftJoin by Mark Eisenberg 12.02.2024 Goldman Sachs reveals that the European version of the Magnificent 7, known as GRANOLAS, trades at a 30% discount. These ...
European GRANOLAS Stocks Outpace Tech Giants by Mark Eisenberg 12.02.2024 European companies known as GRANOLAS have proven to be a lower-risk investment, matching the growth of highflying tech giants. With ...
Accent Therapeutics secures J&J and BMS as new investors in $75M series C by Mark Eisenberg 23.01.2024 Pharmaceutical giants Bristol Myers Squibb and Johnson & Johnson invest in Accent Therapeutics, a leading RNA drug developer, contributing to ...
30 Years of Investing in Emerging Markets: Lessons Learned by Terry Bingman 03.01.2024 The FTSE 100 celebrates 40 years with British American Tobacco as the top-performing stock. Find out which other companies have ...